This was an FDA monitored, Level 1 prospective, multicenter, single-blind, randomized pivotal investigational device exemption (IDE) study.
Spine Premium
Peptide Growth Factor (P-15L) Beats Autograft in TLIF Trial
1 min read Premium comments

TLIFbone graftfusionIDEtransforaminal lumbar interbody fusionPearlMatrixP-15LODIcomposite clinical success
React:
